The Further Study On A Novel Erythrocyte-Derived Depressing Factor

A novel endogenous hypotensive agent was extracted from human erythrocytes by our lab for the first time in 1990 and was termed as erythrocyte-derived depressing factor (EDDF). This subject is obviously creative and all the investigations are domestic and international advanced. A series of studies have been processed, including its extraction, purification, physiological function, security, action mechanisms, characteristic, existence and distribution etc. Many important results were obtained. Up-to-date, we have clarified its structure.EDDF is a numerator material for neither protein nor peptide. It has the characteristics of significant and long-lasting decrease of blood pressure and it is rather safe, stable, and extensively distributes at the person and the animal kingdom. EDDF not only could obviously decrease blood pressure, but also improve significantly the vascular disfunction in hypertensive animals and protect the hearts of spontaneously hypertensive rats (SHR) to some extent. It shows that EDDF is a new endogenous hypotensive substance and can protect blood vessel.EDDF may elicit an endothelium-dependent vasodilation through accumulation of nitric oxide, and subsequently, cGMP and reduce cytosolic and nuclear Ca²⁺ transpotation in vascular smooth muscle cells (VSMCs) with multiroute, including inhibition of Ca²⁺ influx and stimulation of Ca²⁺efflux as well as activating Ca²⁺ store and inhibition of its release from calcium pool from SHR, human umbilical vein and Wistar rats. As a result cytosolic and nuclear Ca²⁺ levels were markedly decreased. EDDF might decrease DNA synthesis, inhibit agonist (angiotensin II ,AngII and...